153 related articles for article (PubMed ID: 32640738)
1. Hypoxia Promotes Prostate Cancer Aggressiveness by Upregulating EMT-Activator Zeb1 and SK3 Channel Expression.
Bery F; Figiel S; Kouba S; Fontaine D; Guéguinou M; Potier-Cartereau M; Vandier C; Guibon R; Bruyère F; Fromont G; Mahéo K
Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32640738
[TBL] [Abstract][Full Text] [Related]
2. A Novel Calcium-Mediated EMT Pathway Controlled by Lipids: An Opportunity for Prostate Cancer Adjuvant Therapy.
Figiel S; Bery F; Chantôme A; Fontaine D; Pasqualin C; Maupoil V; Domingo I; Guibon R; Bruyère F; Potier-Cartereau M; Vandier C; Fromont G; Mahéo K
Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31752242
[TBL] [Abstract][Full Text] [Related]
3. The transcription factor ZEB1 promotes an aggressive phenotype in prostate cancer cell lines.
Orellana-Serradell O; Herrera D; Castellon EA; Contreras HR
Asian J Androl; 2018; 20(3):294-299. PubMed ID: 29271397
[TBL] [Abstract][Full Text] [Related]
4. Copy number gain of ZEB1 mediates a double-negative feedback loop with miR-33a-5p that regulates EMT and bone metastasis of prostate cancer dependent on TGF-β signaling.
Dai Y; Wu Z; Lang C; Zhang X; He S; Yang Q; Guo W; Lai Y; Du H; Peng X; Ren D
Theranostics; 2019; 9(21):6063-6079. PubMed ID: 31534537
[No Abstract] [Full Text] [Related]
5. SK3/TRPC1/Orai1 complex regulates SOCE-dependent colon cancer cell migration: a novel opportunity to modulate anti-EGFR mAb action by the alkyl-lipid Ohmline.
Guéguinou M; Harnois T; Crottes D; Uguen A; Deliot N; Gambade A; Chantôme A; Haelters JP; Jaffrès PA; Jourdan ML; Weber G; Soriani O; Bougnoux P; Mignen O; Bourmeyster N; Constantin B; Lecomte T; Vandier C; Potier-Cartereau M
Oncotarget; 2016 Jun; 7(24):36168-36184. PubMed ID: 27102434
[TBL] [Abstract][Full Text] [Related]
6. Src promotes EGF-induced epithelial-to-mesenchymal transition and migration in gastric cancer cells by upregulating ZEB1 and ZEB2 through AKT.
Zhao L; Li X; Song N; Li A; Hou K; Qu X; Che X; Liu Y
Cell Biol Int; 2018 Mar; 42(3):294-302. PubMed ID: 29052277
[TBL] [Abstract][Full Text] [Related]
7. New Disaccharide-Based Ether Lipids as SK3 Ion Channel Inhibitors.
Berthe W; Sevrain CM; Chantôme A; Bouchet AM; Gueguinou M; Fourbon Y; Potier-Cartereau M; Haelters JP; Couthon-Gourvès H; Vandier C; Jaffrès PA
ChemMedChem; 2016 Jul; 11(14):1531-9. PubMed ID: 27278812
[TBL] [Abstract][Full Text] [Related]
8. Reduced
Kitz J; Lefebvre C; Carlos J; Lowes LE; Allan AL
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884649
[TBL] [Abstract][Full Text] [Related]
9. Zinc finger E-box binding homeobox-1 (Zeb1) drives anterograde lysosome trafficking and tumor cell invasion via upregulation of Na+/H+ Exchanger-1 (NHE1).
Dykes SS; Gao C; Songock WK; Bigelow RL; Woude GV; Bodily JM; Cardelli JA
Mol Carcinog; 2017 Feb; 56(2):722-734. PubMed ID: 27434882
[TBL] [Abstract][Full Text] [Related]
10. Development of pyrene-based fluorescent ether lipid as inhibitor of SK3 ion channels.
Bauduin A; Papin M; Chantôme A; Couthon H; Deschamps L; Requejo-Isidro J; Vandier C; Jaffrès PA
Eur J Med Chem; 2021 Jan; 209():112894. PubMed ID: 33049604
[TBL] [Abstract][Full Text] [Related]
11. New alkyl-lipid blockers of SK3 channels reduce cancer cell migration and occurrence of metastasis.
Girault A; Haelters JP; Potier-Cartereau M; Chantome A; Pinault M; Marionneau-Lambot S; Oullier T; Simon G; Couthon-Gourvès H; Jaffrès PA; Corbel B; Bougnoux P; Joulin V; Vandier C
Curr Cancer Drug Targets; 2011 Nov; 11(9):1111-25. PubMed ID: 21999627
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the role of hsa-miR-200c in reversing the epithelial to mesenchymal transition in prostate cancer.
Basu S; Chaudhary A; Chowdhury P; Karmakar D; Basu K; Karmakar D; Chatterjee J; Sengupta S
Gene; 2020 Mar; 730():144264. PubMed ID: 31759982
[TBL] [Abstract][Full Text] [Related]
13. ETS1 induces transforming growth factor β signaling and promotes epithelial-to-mesenchymal transition in prostate cancer cells.
Rodgers JJ; McClure R; Epis MR; Cohen RJ; Leedman PJ; Harvey JM; ; Thomas MA; Bentel JM
J Cell Biochem; 2019 Jan; 120(1):848-860. PubMed ID: 30161276
[TBL] [Abstract][Full Text] [Related]
14. A novel ZEB1/HAS2 positive feedback loop promotes EMT in breast cancer.
Preca BT; Bajdak K; Mock K; Lehmann W; Sundararajan V; Bronsert P; Matzge-Ogi A; Orian-Rousseau V; Brabletz S; Brabletz T; Maurer J; Stemmler MP
Oncotarget; 2017 Feb; 8(7):11530-11543. PubMed ID: 28086235
[TBL] [Abstract][Full Text] [Related]
15. The transcription factor ZEB1 promotes chemoresistance in prostate cancer cell lines.
Orellana-Serradell O; Herrera D; Castellón EA; Contreras HR
Asian J Androl; 2019; 21(5):460-467. PubMed ID: 30880686
[TBL] [Abstract][Full Text] [Related]
16. CLCA2 epigenetic regulation by CTBP1, HDACs, ZEB1, EP300 and miR-196b-5p impacts prostate cancer cell adhesion and EMT in metabolic syndrome disease.
Porretti J; Dalton GN; Massillo C; Scalise GD; Farré PL; Elble R; Gerez EN; Accialini P; Cabanillas AM; Gardner K; De Luca P; De Siervi A
Int J Cancer; 2018 Aug; 143(4):897-906. PubMed ID: 29536528
[TBL] [Abstract][Full Text] [Related]
17. The role of epithelial-mesenchymal transition drivers ZEB1 and ZEB2 in mediating docetaxel-resistant prostate cancer.
Hanrahan K; O'Neill A; Prencipe M; Bugler J; Murphy L; Fabre A; Puhr M; Culig Z; Murphy K; Watson RW
Mol Oncol; 2017 Mar; 11(3):251-265. PubMed ID: 28133913
[TBL] [Abstract][Full Text] [Related]
18. Long non-coding RNA HOTTIP promotes hypoxia-induced epithelial-mesenchymal transition of malignant glioma by regulating the miR-101/ZEB1 axis.
Zhang S; Wang W; Liu G; Xie S; Li Q; Li Y; Lin Z
Biomed Pharmacother; 2017 Nov; 95():711-720. PubMed ID: 28886531
[TBL] [Abstract][Full Text] [Related]
19. MEF2D Transduces Microenvironment Stimuli to ZEB1 to Promote Epithelial-Mesenchymal Transition and Metastasis in Colorectal Cancer.
Su L; Luo Y; Yang Z; Yang J; Yao C; Cheng F; Shan J; Chen J; Li F; Liu L; Liu C; Xu Y; Jiang L; Guo D; Prieto J; Ávila MA; Shen J; Qian C
Cancer Res; 2016 Sep; 76(17):5054-67. PubMed ID: 27364559
[TBL] [Abstract][Full Text] [Related]
20. The transcriptional factor ZEB1 represses Syndecan 1 expression in prostate cancer.
Farfán N; Ocarez N; Castellón EA; Mejía N; de Herreros AG; Contreras HR
Sci Rep; 2018 Jul; 8(1):11467. PubMed ID: 30065348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
